AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38761068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-based dual antiplatelet therapy
Number of subjects: 1201
Study 38761368 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Sexual Violence Intervention
Number of subjects: 0
Study 38761368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38761558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-enhanced behavior therapy (AEBT)
Number of subjects: 88
Study 38761558 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Number of subjects: 88
Study 38761558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment TTM severity
Number of subjects: 88
Study 38761558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive variables (response inhibition and cognitive flexibility)
Number of subjects: 88
Study 38761800 — intervention group
Group type: EXPERIMENTAL
Intervention: MPER peptide-liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs
Number of subjects: 0
Study 38761811 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy plus best medical treatment
Number of subjects: 201
Study 38761811 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 201
Study 38761816 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg SpFN/ALFQ
Number of subjects: 29
Study 38761816 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg SpFN/ALFQ
Number of subjects: 29
Study 38761816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 38761816 — intervention group
Group type: EXPERIMENTAL
Intervention: SpFN/ALFQ (both doses)
Number of subjects: 29
Study 38761816 — intervention group
Group type: EXPERIMENTAL
Intervention: SpFN/ALFQ
Number of subjects: 29
Study 38761976 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-6
Number of subjects: 230
Study 38761976 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hsCRP
Number of subjects: 230
Study 38761976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower MPO
Number of subjects: 230
Study 38761976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 230
Study 38761976 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α
Number of subjects: 230
Study 38762090 — intervention group
Group type: EXPERIMENTAL
Intervention: Telegenetic counseling intervention
Number of subjects: 8
Study 38762090 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical confirmatory gene sequencing testing
Number of subjects: 8
Study 38762120 — intervention group
Group type: EXPERIMENTAL
Intervention: E-nose technology
Number of subjects: 100
Study 38762187 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (50 g/day, 2 × 25g)
Number of subjects: 31
Study 38762187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein (50 g/day, 2 × 25g)
Number of subjects: 31
Study 38762187 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen protein (50 g/day, 2 × 25g)
Number of subjects: 31
Study 38762187 — intervention group
Group type: COMPARATOR
Intervention: RDA (control phase)
Number of subjects: 31
Study 38762282 — intervention group
Group type: EXPERIMENTAL
Intervention: SDDR-PEP provided to household contacts of patients with leprosy (Arm 2)
Number of subjects: 109436
Study 38762282 — intervention group
Group type: EXPERIMENTAL
Intervention: SDDR-PEP extended to anyone living within 100 m (Arm 3)
Number of subjects: 109436
Study 38762282 — intervention group
Group type: EXPERIMENTAL
Intervention: SDDR-PEP offered to household contacts and anyone living within 100 m testing positive to anti-phenolic glycolipid-I (Arm 4)
Number of subjects: 109436
Study 38762282 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual level SDDR-PEP
Number of subjects: 109436
Study 38762282 — intervention group
Group type: COMPARATOR
Intervention: Comparator arm (no PEP provided)
Number of subjects: 109436
Study 38762348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (cohort B)
Number of subjects: 63
Study 38762348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, irinotecan (cohort D)
Number of subjects: 63
Study 38762353 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI + oxaliplatin + nivolumab
Number of subjects: 118
Study 38762353 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX + nivolumab
Number of subjects: 118
Study 38762360 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant protein (SCB-2019, Clover)
Number of subjects: 772
Study 38762360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz)
Number of subjects: 772
Study 38762360 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA (BNT162b2, Pfizer/Wyeth)
Number of subjects: 772
Study 38762360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 772
Study 38762396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block with ropivacaine 0.5%
Number of subjects: 134
Study 38762396 — intervention group
Group type: COMPARATOR
Intervention: Sham block with saline
Number of subjects: 134
Study 38762425 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual development theory-based breastfeeding education
Number of subjects: 40
Study 38762425 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge education
Number of subjects: 40
Study 38762482 — intervention group
Group type: EXPERIMENTAL
Intervention: LISTERINE® Cool Mint Antiseptic (LCM)
Number of subjects: 0
Study 38762482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-containing prototype mouthrinse (ACPM)
Number of subjects: 0
Study 38762482 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcohol control rinse
Number of subjects: 0
Study 38762482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free prototype mouthrinse (AFPM)
Number of subjects: 0
Study 38762486 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 8 weeks
Number of subjects: 300
Study 38762486 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet for 8 weeks
Number of subjects: 300
Study 38762522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 and BA.5 vaccines
Number of subjects: 0
Study 38762522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S primed participants
Number of subjects: 0
Study 38762522 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-primed and bivalent BA.5 boosted participants
Number of subjects: 0
Study 38762578 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI (Acute Kidney Injury) without CKRT (Continuous Kidney Replacement Therapy)
Number of subjects: 759
Study 38762578 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI (Acute Kidney Injury) with CKRT (Continuous Kidney Replacement Therapy)
Number of subjects: 759
Study 38762578 — intervention group
Group type: COMPARATOR
Intervention: No AKI
Number of subjects: 759
Study 38762708 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0
Study 38762708 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 0
Study 38762708 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive respiratory support
Number of subjects: 0
Study 38762708 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine level
Number of subjects: 0
Study 38762708 — intervention group
Group type: EXPERIMENTAL
Intervention: History of coronary disease
Number of subjects: 0
Study 38762719 — intervention group
Group type: COMPARATOR
Intervention: Postprandial total GDF15 levels in MASLD patients
Number of subjects: 42
Study 38762719 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels in people with obesity
Number of subjects: 42
Study 38762719 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP levels in lean individuals
Number of subjects: 42
Study 38762719 — intervention group
Group type: COMPARATOR
Intervention: Fasting total GDF15 levels
Number of subjects: 42
Study 38762719 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial GDF15 levels
Number of subjects: 42
Study 38762719 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental area under the curve of total and H-specific GDF15
Number of subjects: 42
Study 38762720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Number of subjects: 280
Study 38762720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) without phone-based MI
Number of subjects: 280
Study 38762720 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine monotherapy
Number of subjects: 280
Study 38762727 — intervention group
Group type: EXPERIMENTAL
Intervention: i-MaCHeL programme (web-based intervention)
Number of subjects: 46
Study 38762729 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep extubation (group D)
Number of subjects: 202
Study 38762729 — intervention group
Group type: COMPARATOR
Intervention: Awake extubation (group A)
Number of subjects: 202
Study 38762734 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC treatment (autologous bone marrow concentrate and platelet products)
Number of subjects: 51
Study 38762734 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 51
Study 38762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n=181)
Number of subjects: 356
Study 38762797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=175)
Number of subjects: 356
Study 38762797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 356
Study 38762797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 38762798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g intravenously every 6 hours for 5 days)
Number of subjects: 447
Study 38762798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 38762798 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 447
Study 38763104 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (high-MET group)
Number of subjects: 46
Study 38763104 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (low-MET group)
Number of subjects: 46
Study 38763165 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Number of subjects: 0
Study 38763165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38763153 — intervention group
Group type: COMPARATOR
Intervention: Short-course ADT (6 months)
Number of subjects: 1523
Study 38763153 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course ADT (24 months)
Number of subjects: 1523
Study 38763154 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course ADT (6 months) with postoperative radiotherapy
Number of subjects: 1480
Study 38763154 — intervention group
Group type: COMPARATOR
Intervention: No ADT with postoperative radiotherapy
Number of subjects: 1480
Study 38763257 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT minor allele carriers (T, A)
Number of subjects: 0
Study 38763257 — intervention group
Group type: COMPARATOR
Intervention: COMT major allele carriers (C, G)
Number of subjects: 0
Study 38763303 — intervention group
Group type: EXPERIMENTAL
Intervention: RLRL therapy combined with orthokeratology (RCO)
Number of subjects: 48
Study 38763303 — intervention group
Group type: COMPARATOR
Intervention: Orthokeratology
Number of subjects: 48
Study 38763306 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention targeting system, providers, and parents
Number of subjects: 8
Study 38763307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-coached PST
Number of subjects: 200
Study 38763307 — intervention group
Group type: COMPARATOR
Intervention: Human-coached PST
Number of subjects: 200
Study 38763307 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 200
Study 38763491 — intervention group
Group type: EXPERIMENTAL
Intervention: Local resection (LR)
Number of subjects: 0
Study 38763619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-stimulated isometric torques of the ankle dorsiflexors
Number of subjects: 5
Study 38763619 — intervention group
Group type: COMPARATOR
Intervention: Manual Muscle Tests (MMT)
Number of subjects: 5
Study 38763960 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPERO collaborative information system
Number of subjects: 27
Study 38764430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (500 mg/m2)
Number of subjects: 0
Study 38764430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38764445 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 67
Study 38764606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (PRN)
Number of subjects: 1800
Study 38764606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (EOD+PRN)
Number of subjects: 1800
Study 38764606 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (overall treatment)
Number of subjects: 1800
Study 38764682 — intervention group
Group type: EXPERIMENTAL
Intervention: JAB-2485, a small-molecule inhibitor of AURKA
Number of subjects: 0
Study 38765190 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI
Number of subjects: 0
Study 38765190 — intervention group
Group type: EXPERIMENTAL
Intervention: ASDAS
Number of subjects: 0
Study 38765202 — intervention group
Group type: EXPERIMENTAL
Intervention: 75.0 Gy in 30 fractions with concurrent bevacizumab (BEV)
Number of subjects: 0
Study 38765202 — intervention group
Group type: COMPARATOR
Intervention: Standard plans (not specified dosage)
Number of subjects: 0
Study 38765202 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental plans (75.0 Gy in 30 fractions)
Number of subjects: 0
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: CRADI-8 positive for colorectal symptoms
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal incontinence
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI-20
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: POPDI
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: UDI6
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: P-QoL social limitation
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: P-QoL sleep-energy
Number of subjects: 113
Study 38765524 — intervention group
Group type: EXPERIMENTAL
Intervention: P-QoL severity
Number of subjects: 113
Study 38765567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan 800 mg once daily
Number of subjects: 371
Study 38765567 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 371
Study 38765784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (previously received)
Number of subjects: 0
Study 38765784 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-naïve participants
Number of subjects: 0
Study 38766034 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient-reported outcomes (PROs) including LURN Symptom Index (SI)-29 and AUA-SI
Number of subjects: 0
Study 38766034 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinical tests integrated with PRO assessment
Number of subjects: 0
Study 38766034 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric properties of the LURN SIs
Number of subjects: 0
Study 38766034 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-coordination recommendations based on PROs
Number of subjects: 0
Study 38766125 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibitors (XOIs) for urate-lowering treatment (ULT)
Number of subjects: 49
Study 38766125 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibitors (XOIs)
Number of subjects: 49
Study 38766125 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (a type of xanthine oxidase inhibitor)
Number of subjects: 49
Study 38766126 — intervention group
Group type: EXPERIMENTAL
Intervention: eIF4A inhibitor zotatifin
Number of subjects: 0
Study 38766126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with eIF4A inhibitor zotatifin and fulvestrant
Number of subjects: 0
Study 38766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Literacy and Nutrition (FLAN) curriculum
Number of subjects: 39
Study 38766254 — intervention group
Group type: COMPARATOR
Intervention: Nutrition information-only control
Number of subjects: 39
Study 38766513 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored weight loss intervention
Number of subjects: 169
Study 38766513 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study 38766567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet-supported counseling about the benefits of family planning
Number of subjects: 347
Study 38766567 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 347
Study 38767159 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic collagen-hydroxyapatite scaffold (CHAS) augmented with filtered bone marrow aspirate (fBMA)
Number of subjects: 78
Study 38767159 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic collagen-hydroxyapatite scaffold (CHAS)
Number of subjects: 78
Study 38767193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise for 12 weeks
Number of subjects: 60
Study 38767193 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 60
Study 38767196 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 779
Study 38767196 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 779
Study 38767222 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) utilizing a limited contact dynamic compression plate and screw construct
Number of subjects: 0
Study 38767222 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with closed reduction and below-elbow casting
Number of subjects: 0
Study 38767222 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 0
Study 38767248 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by a pulmonologist and an asthma-COPD educator who initiated guideline-based care
Number of subjects: 508
Study 38767248 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care practitioner
Number of subjects: 508
Study 38767248 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by a pulmonologist and an asthma-COPD educator
Number of subjects: 508
Study 38767445 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT DCB (Medtronic) treatment
Number of subjects: 100
Study 38767513 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive training (NT) administered weekly for 10 consecutive weeks, supplemented by a structured home exercise programme for 6 days a week over the same 10-week period.
Number of subjects: 14
Study 38767513 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive training (NT)
Number of subjects: 14
Study 38767513 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) children
Number of subjects: 14
Study 38767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg subcutaneous every 2 weeks)
Number of subjects: 935
Study 38767614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935
Study 38767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 935
Study 38767650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (nivo-ipi)
Number of subjects: 0
Study 38767694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent phototherapy (IPT) - 2 cycles of 1 h on and 2 h off in a 6-h session
Number of subjects: 104
Study 38767694 — intervention group
Group type: COMPARATOR
Intervention: Continuous phototherapy (CPT) - applied continuously for 6 h
Number of subjects: 104
Study 38767780 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-induced hospitalisation
Number of subjects: 138
Study 38767872 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sleep (mean duration 4 hours, 12 minutes)
Number of subjects: 61
Study 38767872 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body fat percentage (TBF%) above 42
Number of subjects: 61
Study 38767937 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmethadone (REL-1017)
Number of subjects: 0
Study 38767949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) performed by general practitioners (GPs)
Number of subjects: 151
Study 38767958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5waysA intervention (web-based, 2 webinars, SMS reminders over 10 weeks)
Number of subjects: 969
Study 38767958 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (active or passive)
Number of subjects: 969
Study 38767985 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE (5.5-h sitting with 2-min walking at 6.4 km·h -1 every 20 min)
Number of subjects: 26
Study 38767985 — intervention group
Group type: COMPARATOR
Intervention: SIT (5.5-h uninterrupted sitting)
Number of subjects: 26
Study 38768231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil-9 (3 doses administered intramuscularly at 0, 2, and 6 months)
Number of subjects: 0
Study 38768283 — intervention group
Group type: COMPARATOR
Intervention: Total aortic arch repair
Number of subjects: 1199
Study 38768283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending aortic repair
Number of subjects: 1199
Study 38768299 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing (CSP)
Number of subjects: 69
Study 38768299 — intervention group
Group type: COMPARATOR
Intervention: Biventricular Pacing (BiVP)
Number of subjects: 69